- Report
- September 2025
- 283 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 269 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 291 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 269 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 132 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 224 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 194 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 196 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 193 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 126 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 291 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 126 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 183 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 183 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 193 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 277 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 590 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- August 2025
Global
From €4279EUR$4,900USD£3,717GBP
- Report
- March 2025
- 184 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- February 2025
- 185 Pages
Global
From €3930EUR$4,500USD£3,414GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more